Literature DB >> 21326940

Bacteria as tumor therapeutics?

Tobias A Oelschlaeger1.   

Abstract

Entities:  

Keywords:  E. coli; LPS; Nissle 1917; anaerobic; msbB; probiotic; tumor therapy

Mesh：

Year:  2010        PMID： 21326940      PMCID： PMC3026455          DOI： 10.4161/bbug.1.2.11248

Source DB:  PubMed          Journal:  Bioeng Bugs        ISSN： 1949-1018


× No keyword cloud information.
  16 in total

1.  Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. 1976.

Authors:  A Morales; D Eidinger; A W Bruce
Journal:  J Urol       Date:  2002-02       Impact factor: 7.450

2.  [Surgical therapy of traumatic intracerebral hematomas].

Authors:  F Heppner; H Tritthart; P Holzer
Journal:  Wien Med Wochenschr       Date:  1978

3.  Escherichia coli msbB gene as a virulence factor and a therapeutic target.

Authors:  J E Somerville; L Cassiano; R P Darveau
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

4.  A single nucleotide exchange in the wzy gene is responsible for the semirough O6 lipopolysaccharide phenotype and serum sensitivity of Escherichia coli strain Nissle 1917.

Authors:  Lubomir Grozdanov; Ulrich Zähringer; Gabriele Blum-Oehler; Lore Brade; Anke Henne; Yuriy A Knirel; Ursula Schombel; Jürgen Schulze; Ulrich Sonnenborn; Gerhard Gottschalk; Jörg Hacker; Ernst T Rietschel; Ulrich Dobrindt
Journal:  J Bacteriol       Date:  2002-11       Impact factor: 3.490

5.  A bacterial protein enhances the release and efficacy of liposomal cancer drugs.

Authors:  Ian Cheong; Xin Huang; Chetan Bettegowda; Luis A Diaz; Kenneth W Kinzler; Shibin Zhou; Bert Vogelstein
Journal:  Science       Date:  2006-11-24       Impact factor: 47.728

6.  Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma.

Authors:  John F Toso; Vee J Gill; Patrick Hwu; Francesco M Marincola; Nicholas P Restifo; Douglas J Schwartzentruber; Richard M Sherry; Suzanne L Topalian; James C Yang; Frida Stock; Linda J Freezer; Kathleen E Morton; Claudia Seipp; Leah Haworth; Sharon Mavroukakis; Donald White; Susan MacDonald; John Mao; Mario Sznol; Steven A Rosenberg
Journal:  J Clin Oncol       Date:  2002-01-01       Impact factor: 44.544

7.  Analysis of the genome structure of the nonpathogenic probiotic Escherichia coli strain Nissle 1917.

Authors:  Lubomir Grozdanov; Carsten Raasch; Jürgen Schulze; Ulrich Sonnenborn; Gerhard Gottschalk; Jörg Hacker; Ulrich Dobrindt
Journal:  J Bacteriol       Date:  2004-08       Impact factor: 3.490

8.  The liquefaction (oncolysis) of malignant gliomas by a non pathogenic Clostridium.

Authors:  F Heppner; J R Möse
Journal:  Acta Neurochir (Wien)       Date:  1978       Impact factor: 2.216

9.  Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine.

Authors:  W Kruis; P Fric; J Pokrotnieks; M Lukás; B Fixa; M Kascák; M A Kamm; J Weismueller; C Beglinger; M Stolte; C Wolff; J Schulze
Journal:  Gut       Date:  2004-11       Impact factor: 23.059

10.  A novel Escherichia coli lipid A mutant that produces an antiinflammatory lipopolysaccharide.

Authors:  J E Somerville; L Cassiano; B Bainbridge; M D Cunningham; R P Darveau
Journal:  J Clin Invest       Date:  1996-01-15       Impact factor: 14.808
View more
  14 in total

1.  The power of combining adoptive cell therapy (ACT) and pathogen-boosted vaccination to treat solid tumors.

Authors:  Ryan Zander; Weiguo Cui
Journal:  Hum Vaccin Immunother       Date:  2017-10-03       Impact factor: 3.452

2.  Bioinspired and Biomimetic Nanomedicines.

Authors:  Zhaowei Chen; Zejun Wang; Zhen Gu
Journal:  Acc Chem Res       Date:  2019-04-12       Impact factor: 22.384

Review 3.  Advances in Stimulus-Responsive Polymeric Materials for Systemic Delivery of Nucleic Acids.

Authors:  Minjie Sun; Kaikai Wang; David Oupický
Journal:  Adv Healthc Mater       Date:  2017-12-11       Impact factor: 9.933

Review 4.  Innate Immunity and Cancer Pathophysiology.

Authors:  Laura Maiorino; Juliane Daßler-Plenker; Lijuan Sun; Mikala Egeblad
Journal:  Annu Rev Pathol       Date:  2021-11-17       Impact factor: 32.350

Review 5.  Targeting the tumor microenvironment to enhance antitumor immune responses.

Authors:  Kevin Van der Jeught; Lukasz Bialkowski; Lidia Daszkiewicz; Katrijn Broos; Cleo Goyvaerts; Dries Renmans; Sandra Van Lint; Carlo Heirman; Kris Thielemans; Karine Breckpot
Journal:  Oncotarget       Date:  2015-01-30

Review 6.  BCG turns 100: its nontraditional uses against viruses, cancer, and immunologic diseases.

Authors:  Alok K Singh; Mihai G Netea; William R Bishai
Journal:  J Clin Invest       Date:  2021-06-01       Impact factor: 19.456

7.  Solid tumors provide niche-specific conditions that lead to preferential growth of Salmonella.

Authors:  Cecilia A Silva-Valenzuela; Prerak T Desai; Roberto C Molina-Quiroz; David Pezoa; Yong Zhang; Steffen Porwollik; Ming Zhao; Robert M Hoffman; Inés Contreras; Carlos A Santiviago; Michael McClelland
Journal:  Oncotarget       Date:  2016-06-07

8.  Bacterial Therapy of Cancer: Promises, Limitations, and Insights for Future Directions.

Authors:  M Gabriela Kramer; Martín Masner; Fernando A Ferreira; Robert M Hoffman
Journal:  Front Microbiol       Date:  2018-01-23       Impact factor: 5.640

9.  A Salmonella nanoparticle mimic overcomes multidrug resistance in tumours.

Authors:  Regino Mercado-Lubo; Yuanwei Zhang; Liang Zhao; Kyle Rossi; Xiang Wu; Yekui Zou; Antonio Castillo; Jack Leonard; Rita Bortell; Dale L Greiner; Leonard D Shultz; Gang Han; Beth A McCormick
Journal:  Nat Commun       Date:  2016-07-25       Impact factor: 14.919

Review 10.  Clinical Experience and Recent Advances in the Development of Listeria-Based Tumor Immunotherapies.

Authors:  Mariam Oladejo; Yvonne Paterson; Laurence M Wood
Journal:  Front Immunol       Date:  2021-04-14       Impact factor: 8.786
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.